{"nctId":"NCT01854918","briefTitle":"Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia","startDateStruct":{"date":"2013-04-23","type":"ACTUAL"},"conditions":["Hyperlipidemia and Mixed Dyslipidemia"],"count":3681,"armGroups":[{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Evolocumab","Drug: Standard of Care"]},{"label":"Evolocumab + Standard of Care","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab","Drug: Standard of Care"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Standard of Care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Complete a qualifying evolocumab (AMG 145) parent study (ie, Study 20110114 \\[NCT01763827\\], 20110115 \\[NCT01763866\\], 20110116 \\[NCT01763905\\], 20110117 \\[NCT01763918\\], 20110109 \\[NCT01516879\\], 20120122 \\[NCT01953328\\], 20120332 \\[NCT01984424\\], 20120348 \\[NCT01849497\\], or 20120356 \\[NCT01879319\\]).\n\nExclusion Criteria:\n\n* Experienced a treatment-related serious adverse event that led to study drug discontinuation in the parent study\n* Have an unstable medical condition, in the judgment of the investigator\n* Known sensitivity to any of the products to be administered during dosing\n* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.0, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"796","spread":null},{"groupId":"OG001","value":"1655","spread":null},{"groupId":"OG002","value":"929","spread":null},{"groupId":"OG003","value":"1789","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"519","spread":null},{"groupId":"OG001","value":"1070","spread":null},{"groupId":"OG002","value":"700","spread":null},{"groupId":"OG003","value":"1339","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"225","spread":null},{"groupId":"OG002","value":"214","spread":null},{"groupId":"OG003","value":"379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"178","spread":null},{"groupId":"OG003","value":"332","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in LDL-C at Weeks 48 and 104","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","spread":"38.93"},{"groupId":"OG001","value":"-51.59","spread":"28.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.96","spread":"33.29"},{"groupId":"OG001","value":"-50.31","spread":"30.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in LDL-C at Weeks 48 and 104","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"43.9"},{"groupId":"OG001","value":"-68.8","spread":"46.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.4","spread":"50.1"},{"groupId":"OG001","value":"-67.2","spread":"46.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":104,"n":1227},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Hypertension","Arthralgia","Back pain"]}}}